Danaher (DHR) Gears Up to Post Q2 Earnings: What to Expect
However, decreased demand in the bioprocessing business is likely to have hurt the Biotechnology segment’s revenues.
Express News | Danaher Corp : JP Morgan Cuts Target Price to $295 From $300
Express News | Danaher Announced The Launch Of Two New Clinical Laboratory Improvement Amendments And College Of American Pathologists-certified Labs Intended To Accelerate The Development Of Companion Diagnostics And Complementary Diagnostics
Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development
DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics.Clinical Laboratory Improvement Amendments (CLIA)
(DHR) - Analyzing Danaher's Short Interest
Danaher's (NYSE:DHR) short percent of float has risen 11.11% since its last report. The company recently reported that it has 8.61 million shares sold short, which is 1.3% of all regular shares that
Danaher (DHR) Upgraded to Buy: Here's What You Should Know
Is Danaher (DHR) Stock Outpacing Its Conglomerates Peers This Year?
Danaher Releases 2024 Sustainability Report
WASHINGTON, July 16, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), the global life sciences and diagnostics innovator, today published its 2024 Sustainability
Why Is Danaher Corporation (DHR) a Good Industrial Stock to Buy Now?
These Are the Stocks With the Highest Increase in Short Interest Within Life Sciences and Diagnostics - Baird
The Zacks Analyst Blog Highlights Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri
Here's Why Danaher (NYSE:DHR) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor,
Danaher's Leica Microsystems Enters Research Collaboration With Stanford University for AI Microscopes
Danaher (DHR) said Thursday its subsidiary Leica Microsystems entered a research collaboration with Stanford University's Department of Bioengineering to develop AI-integrated microscopes for cancer
Express News | Danaher Launched Research Collaboration With Stanford University's Department Of Bioengineering To Combine Spatial Biology With Artificial Intelligence To Help De-risk Cancer Drug Development
Express News | Danaher Launches Beacon Research Collaboration With Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening
$100 Invested In Danaher 10 Years Ago Would Be Worth This Much Today
Danaher (NYSE:DHR) has outperformed the market over the past 10 years by 5.49% on an annualized basis producing an average annual return of 16.45%. Currently, Danaher has a market capitalization of $1
Here's Why L1 Capital International Fund Divested Its Holdings in Danaher Corporation (DHR)
Beckman Coulter Introduces New Integrated Chemistry and Immunoassay Analyzer
Beckman Coulter Diagnostics, a clinical diagnostics leader, today introduces the new DxC 500i Clinical Analyzer*, an integrated clinical chemistry...
Danaher on Track for Longest Losing Streak Since January 1998 -- Data Talk
Danaher Corporation (DHR) is currently at $238.96, down $0.28 or 0.12% --Would be lowest close since April 22, 2024, when it closed at $236.08 --Currently down nine consecutive days; down 6.93% over t
Goldman Sachs Adjusts Price Target on Danaher to $225 From $220, Maintains Neutral Rating
Danaher (DHR) has an average outperform rating and a price target range of $220 to $300, according to analysts polled by Capital IQ.Price: 239.03, Change: -0.22, Percent Change: -0.09